Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00944229 · ClinicalTrials.gov registry record · Phase 3
The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure
A Phase 3 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT00944229 is a Phase 3 study that was terminated before completion, run by Columbia University. The registered enrollment target is 58 participants.
The verdict
NCT00944229, a Phase 3 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
A diet rich in Omega-3 (fish oil) reduces plasma triglycerides and the risk for ischemic heart disease. Recently, a large trial evaluating treatment with Omega 3 in heart failure patients suggested that omega 3 may lower the risk of death from CHF. The mechanism of this potential benefit is not well understood. Methods: Forty patients will be enrolled in the study. Twenty patients will receive Omega 3 (lovaza 4 gm a day) and 20 patients will receive placebo. All subjects will have assessment of their exercise capacity and blood vessel function before and after an 8 week treatment period. About 4 table spoons of blood will be drawn throughout the study. Expected results: The investigators believe that omega 3 may improve the ability to exercise and improve blood vessel function.
Interventions
- DRUG Placebo
- DRUG LOVAZA (Omega-3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00944229
The ClinicalTrials.gov registry entry for NCT00944229 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00944229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00944229 about?
NCT00944229 is a clinical study titled "The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure". A diet rich in Omega-3 (fish oil) reduces plasma triglycerides and the risk for ischemic heart disease. Recently, a large trial evaluating treatment with Omega 3 in heart failure patients suggested that omega 3 may lower the risk of death from CHF. The mechanism of this potential benefit is not well...
What is the current status of trial NCT00944229?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2010-01. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00944229?
The interventions under investigation include: Placebo (DRUG), LOVAZA (Omega-3) (DRUG).
Who is sponsoring clinical trial NCT00944229?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.